What is the latest AARTIPHARM stock price?
The latest stored price for AARTIPHARM is Rs 697.95 as of 2026-07-20.
gimli
AARTIPHARM stock AI analysis
AARTIPHARM Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
AARTI PHARMALABS LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available AARTIPHARM price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹697.95
1W return
-2.77%
1M return
+0.89%
3M return
+3.22%
6M return
-7.27%
1Y return
-26.63%
Market cap
₹6,327.46 cr
PE
33.93
PB
2.98
ROE
+9.07%
ROCE
+11.18%
RSI
51.30
Turnover
₹7.31 cr
Why it can matter in screens
- Momentum: AARTIPHARM is above 50DMA, below 200DMA; RSI is 51.30.
- Returns: 1D -1.41%, 1W -2.77%, 1M +0.89%, 3M +3.22%, 1Y -26.63%.
- Trend levels: 52W high ₹950.70, 52W low ₹591.95, off high -26.59%.
- Liquidity: latest turnover is ₹7.31 cr; volume vs 20D is +0.41%.
- Valuation/profitability: PE 33.93, PB 2.98, ROE +9.07%, ROCE +11.18%.
- Growth: 3Y sales CAGR -2.05%, 3Y profit CAGR -3.35%.
Quick Answers
Is AARTIPHARM above its 50DMA and 200DMA?
AARTIPHARM is above 50DMA, below 200DMA. The latest 50DMA is 683.78 and the latest 200DMA is 727.81.
What are AARTIPHARM PE, ROE and ROCE?
AARTIPHARM has PE 33.93, ROE +9.07%, and ROCE +11.18% in Gimli's latest available snapshot.
How has AARTIPHARM performed recently?
AARTIPHARM has returned +0.89% over 1 month, +3.22% over 3 months, and -26.63% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 582.64 cr | 126.70 cr | 61.12 cr | 6.74 |
| 2025-12-31 | 432.27 cr | 104.07 cr | 47.96 cr | 5.29 |
| 2025-09-30 | 418.33 cr | 74.13 cr | 27.92 cr | 3.08 |
| 2025-06-30 | 386.19 cr | 95.04 cr | 49.50 cr | 5.46 |
| 2025-03-31 | 563.78 cr | 144.02 cr | 88.34 cr | 9.75 |
| 2024-12-31 | 537.78 cr | 133.64 cr | 73.99 cr | 8.16 |
| 2024-09-30 | 458.03 cr | 98.16 cr | n/a | nan |
| 2024-06-30 | 555.49 cr | 98.68 cr | 55.45 cr | 6.12 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,819.44 cr | 384.16 cr | 174.71 cr | 19.27 |
| 2025-03-31 | 2,115.07 cr | 474.49 cr | 272.40 cr | 30.06 |
| 2024-03-31 | 1,815.51 cr | 390.94 cr | 216.90 cr | 23.93 |
| 2023-03-31 | 1,936.00 cr | 344.37 cr | 193.49 cr | 21.35 |
| 2022-03-31 | 943.53 cr | 197.84 cr | 106.73 cr | 11.78 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 3,481.71 cr | 8.53 cr | 754.36 cr | 2,124.60 cr |
| 2025-03-31 | 2,906.41 cr | 6.73 cr | 420.82 cr | 1,989.91 cr |
| 2024-03-31 | 2,582.11 cr | 23.63 cr | 285.25 cr | 1,757.04 cr |
| 2023-03-31 | 2,244.02 cr | 12.12 cr | 215.31 cr | 1,558.49 cr |
| 2022-03-31 | 2,039.90 cr | 83.27 cr | 341.40 cr | 1,386.48 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 261.93 cr | -186.38 cr | n/a |
| 2025-03-31 | 330.14 cr | -113.74 cr | n/a |
| 2024-03-31 | 216.35 cr | 17.57 cr | n/a |
| 2023-03-31 | 250.12 cr | 130.46 cr | n/a |
| 2022-03-31 | -43.70 cr | -184.86 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-03-31 | +43.08% | +8.39% | +7.41% | +0.80% | +41.11% | +11.03% |
| 2025-12-31 | +43.10% | +7.68% | +7.66% | +1.09% | +41.54% | +0.01% |
| 2025-09-30 | +42.88% | +8.02% | +6.96% | +0.79% | +42.13% | +0.01% |
| 2025-06-30 | +43.72% | +7.35% | +7.79% | +0.90% | +41.12% | +0.01% |
| 2025-03-31 | +44.29% | +7.36% | +7.53% | +0.78% | +40.81% | +0.00% |
| 2024-12-31 | +44.66% | +8.64% | +10.36% | +3.93% | +36.33% | +0.00% |
| 2024-09-30 | +46.10% | +7.38% | +11.35% | +4.93% | +35.16% | +0.00% |
| 2024-06-30 | +46.46% | +7.06% | +11.47% | +4.69% | +35.00% | +0.00% |
| 2024-03-31 | +46.46% | +8.32% | +9.97% | +2.72% | +35.23% | +0.00% |
| 2023-12-31 | +46.46% | +8.16% | +9.91% | +2.05% | +35.46% | +0.00% |
| 2023-09-30 | +46.30% | +8.45% | +10.51% | +2.67% | +34.73% | +0.00% |
| 2023-06-30 | +45.98% | +7.43% | +10.66% | +2.72% | +35.92% | +0.00% |
| 2023-03-31 | +45.98% | +7.69% | +13.70% | +5.11% | +32.61% | +0.00% |
| 2023-01-13 | +44.16% | +11.89% | +15.03% | +6.70% | +28.91% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 469,405.90 cr | 40.823336 | +14.71% | +15.52% |
| DIVISLAB | DIVI S LABORATORIES LTD | 194,269.92 cr | 75.650281 | +16.19% | +8.71% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 169,405.46 cr | 78.319677 | +17.18% | +42.14% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,040.28 cr | 65.380043 | +21.03% | +21.93% |
| CIPLA | CIPLA LTD | 116,452.52 cr | 30.005339 | +11.79% | -2.75% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,616.29 cr | 23.056854 | +17.93% | +17.85% |
| LUPIN | LUPIN LIMITED | 113,320.96 cr | 21.221472 | +26.83% | +28.27% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 107,290.40 cr | 74.382732 | +14.33% | -9.32% |
Try these prompts
- Analyze AARTI PHARMALABS with valuation, momentum and industry peers
- Compare AARTIPHARM with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare AARTIPHARM with other Healthcare stocks
Data snapshot: 2026-07-20. Not investment advice.